急性骨髄性白血病市場：疾患サブタイプ別、治療法別、投与経路別、流通チャネル別、地域別、機会、予測、2017年～2031年

世界の急性骨髄性白血病の市場規模は、予測期間の2024年～2031年に10.10％のCAGRで拡大し、2023年の23億2,000万米ドルから2031年には50億1,000万米ドルに成長すると予測されています。急性骨髄性白血病（AML）の市場需要は、有病率の上昇と投資家や市場関係者の関心の高まりにより、予測期間中に飛躍的に拡大すると予想されます。

AMLの進行速度は非常に速く、患者の循環系に影響を及ぼします。AMLの治療法には、化学療法、放射線療法、幹細胞移植、新規標的療法などがあります。現在、米国食品医薬品局（USFDA）によりAML治療薬として承認されている薬剤は約40種類あります。近年、AMLに焦点を当てたいくつかの有望な研究が注目されており、具体的な臨床結果が得られる可能性があります。AMLの調査における最近の傾向としては、毒性作用を軽減し、患者のコンプライアンスを改善し、臨床転帰を向上させるために、薬剤や異なる動向を組み合わせて投与する併用療法が挙げられます。

当レポートでは、世界の急性骨髄性白血病市場について調査し、市場の概要とともに、疾患サブタイプ別、治療法別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の急性骨髄性白血病市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 疾患サブタイプ別
  • 治療法別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 北米の急性骨髄性白血病市場の見通し、2017年～2031年

第6章 欧州の急性骨髄性白血病市場の見通し、2017年～2031年

第7章 アジア太平洋の急性骨髄性白血病市場の見通し、2017年～2031年

第8章 南米の急性骨髄性白血病市場の見通し、2017年～2031年

第9章 中東・アフリカの急性骨髄性白血病市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ10の情勢
  • Astellas Pharma Inc.
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Novartis AG
  • Daiichi Sankyo, Inc.
  • Jazz Pharmaceuticals plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Partner Therapeutics, Inc.
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 3. Global Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 4. Global Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 5. Global Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 6. Global Acute Myeloid Leukemia Market Share (%), By Region, 2017-2031F
• Figure 7. North America Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 8. North America Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 9. North America Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 10. North America Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 11. North America Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 12. North America Acute Myeloid Leukemia Market Share (%), By Country, 2017-2031F
• Figure 13. United States Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 14. United States Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 15. United States Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 16. United States Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 17. United States Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 18. Canada Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 19. Canada Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 20. Canada Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 21. Canada Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 22. Canada Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23. Mexico Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Mexico Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 25. Mexico Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 26. Mexico Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 27. Mexico Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 28. Europe Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Europe Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 30. Europe Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 31. Europe Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 32. Europe Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Acute Myeloid Leukemia Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 35. Germany Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 36. Germany Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 37. Germany Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 38. Germany Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. France Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 40. France Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 41. France Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 42. France Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 43. France Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44. Italy Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Italy Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 46. Italy Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 47. Italy Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 48. Italy Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 49. United Kingdom Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 50. United Kingdom Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 51. United Kingdom Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 52. United Kingdom Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 53. United Kingdom Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 54. Russia Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 55. Russia Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 56. Russia Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 57. Russia Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 58. Russia Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 59. Netherlands Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 60. Netherlands Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 61. Netherlands Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 62. Netherlands Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 63. Netherlands Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Spain Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Spain Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 66. Spain Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 67. Spain Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 68. Spain Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 69. Turkey Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Turkey Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 71. Turkey Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 72. Turkey Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 73. Turkey Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 74. Poland Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 75. Poland Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 76. Poland Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 77. Poland Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 78. Poland Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 79. South America Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 80. South America Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 81. South America Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 82. South America Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 83. South America Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 84. South America Acute Myeloid Leukemia Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 86. Brazil Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 87. Brazil Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 88. Brazil Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 89. Brazil Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 90. Argentina Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Argentina Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 92. Argentina Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 93. Argentina Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 94. Argentina Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 95. Asia-Pacific Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 97. Asia-Pacific Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 98. Asia-Pacific Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 99. Asia-Pacific Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. Asia-Pacific Acute Myeloid Leukemia Market Share (%), By Country, 2017-2031F
• Figure 101. India Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 102. India Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 103. India Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 104. India Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 105. India Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 106. China Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 107. China Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 108. China Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 109. China Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 110. China Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 111. Japan Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 112. Japan Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 113. Japan Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 114. Japan Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 115. Japan Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 116. Australia Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 117. Australia Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 118. Australia Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 119. Australia Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 120. Australia Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 121. Vietnam Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 122. Vietnam Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 123. Vietnam Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 124. Vietnam Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 125. Vietnam Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. South Korea Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 127. South Korea Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 128. South Korea Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 129. South Korea Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 130. South Korea Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 131. Indonesia Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 132. Indonesia Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 133. Indonesia Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 134. Indonesia Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 135. Indonesia Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 136. Philippines Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 137. Philippines Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 138. Philippines Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 139. Philippines Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 140. Philippines Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 141. Middle East & Africa Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 143. Middle East & Africa Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 144. Middle East & Africa Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 145. Middle East & Africa Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 146. Middle East & Africa Acute Myeloid Leukemia Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 149. Saudi Arabia Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 150. Saudi Arabia Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 151. Saudi Arabia Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 152. UAE Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 153. UAE Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 154. UAE Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 155. UAE Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 156. UAE Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 157. South Africa Acute Myeloid Leukemia Market, By Value, In USD Billion, 2017-2031F
• Figure 158. South Africa Acute Myeloid Leukemia Market Share (%), By Disease Subtype, 2017-2031F
• Figure 159. South Africa Acute Myeloid Leukemia Market Share (%), By Treatment, 2017-2031F
• Figure 160. South Africa Acute Myeloid Leukemia Market Share (%), By Route of Administration, 2017-2031F
• Figure 161. South Africa Acute Myeloid Leukemia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. By Disease Subtype Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global acute myeloid leukemia market is projected to witness a CAGR of 10.10% during the forecast period 2024-2031, growing from USD 2.32 billion in 2023 to USD 5.01 billion in 2031. The market demand for acute myeloid leukemia (AML) is anticipated to thrive drastically in the forecast years due to the rising prevalence and the growing interest of investors and market players.

The progression rate of AML is quite fast, affecting the circulatory system of patients. Treatment options for AML include chemotherapy, radiotherapy, stem cell transplant, and novel targeted therapies. Currently, there are around 40 drugs approved by the United States Food and Drug Administration (USFDA) for the treatment of AML. Several promising studies focused on AML have been the subject of interest in recent years and may provide concrete clinical outcomes. The recent trend observed in AML research includes combination therapy in which a combination of drugs or different therapies is administered to reduce toxic effects, improve patient compliance, and enhance clinical outcomes. For instance, as per the research findings reported in the Oncogenesis journal in March 2024, the combination of JAK1/2 inhibitor (ruxolitinib) with either ERK or CSNK2A1 inhibitor had the highest efficacy and lowest toxicity, demonstrating the important role of these targets in AML. The research findings claim that this combination has the lowest toxicity and seems to be promising for AML treatment. Additionally, regulatory approvals of drugs for AML treatment boost market growth, adding another treatment option for the target population. In July 2023, Daiichi Sankyo, Inc. announced that it received USFDA approval for its VANFLYTA (quizartinib) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML).

Rising Prevalence of Acute Myeloid Leukemia to Expand Market Size

AML is the most common type of leukemia, prevalent mainly in adults, and despite being characterized as a rare disease, its prevalence is reported to be increasing. The main reasons for the growing burden of AML include genetic mutations in isocitrate dehydrogenase (IDH) and age-associated factors. The rising prevalence of AML boosts the demand for more therapies and drugs to be used for treatment purposes and drives market demand. The exploration of its subtypes and efforts to improve clinical outcomes through the reduction of side effects of drugs are further contributing to the growth in demand for AML treatments, expanding the market further. According to the estimates by the American Cancer Society, about 20,800 people will be diagnosed with AML in 2024 within the United States, and 11,220 deaths are expected. AML is more common in men than women and accounts for 1 out of 3 leukemia cases.

Fundings for AML Research to Drive Market Growth

Monetary funding is a crucial driver for research in the global AML market. In recent years, several grants, funding, and government support have been promoting the research of AML treatments and diagnosis. These funding initiatives accelerate the market growth as research usually translates to promising market products. Besides government bodies, university grants and fellowships from various associations like the Leukemia & Lymphoma Society are reportedly driving market growth. For instance, in November 2023, the Leukemia & Lymphoma Society, the largest private funder of blood cancer research, announced new grants to 78 research groups across seven countries worth USD 65 million for blood cancer research. This announcement expands the Leukemia and Lymphoma Society's academic research portfolio over USD 240 million across multi-year grants. The major beneficiaries of these grants include researchers from prestigious cancer institutions, including Dana-Farber Cancer Center, MD Anderson Cancer Center, St. Jude Children's Research Hospital, and others.

Chemotherapy to Dominate the Acute Myeloid Leukemia Market Share

The chemotherapy segment is anticipated to possess a significant market share in the AML market owing to its widespread usage, high adoption rates, and comparative affordability compared to targeted therapies. Chemotherapies are usually the first line of treatment provided to AML patients by medical professionals, followed by other approved conjugated therapies or drugs. Despite all these factors, chemotherapy has several side effects, which may hinder future market share growth. The chemotherapy segment is expected to retain the lead position in the AML market during the forecast period. However, targeted therapy and immunotherapy segments are anticipated to register a robust growth rate due to high efficacy. New regulatory approvals further strengthen the market share of the chemotherapy segment. For instance, in April 2024, the USFDA granted breakthrough therapy designation to ziftomenib for the treatment of heavily pretreated patients with relapsed/refractory NPM1-mutant AML. It marks the first investigational treatment granted to breakthrough therapy designation for NPM1-mutant AML. Ziftomenib is a once-daily oral drug that targets the Menin-KMT2A/MLL protein-protein interaction to treat AML in genetically defined patients with high unmet needs.

North America to Dominate the Global Acute Myeloid Leukemia Market Share

North America is anticipated to dominate the share of the AML market, driven by several key factors. The rising prevalence of AML, particularly in the United States, is a significant contributor. In 2024, approximately 20,800 new cases are expected to be diagnosed in the United States, highlighting the impact of the disease and the urgent need for effective treatments. Moreover, advancements in research and development have led to the introduction of innovative therapies, such as the FDA's approval of ivosidenib in combination with azacitidine for newly diagnosed AML patients. This trend is expected to continue under the influence of investments in healthcare infrastructure and increased awareness of AML. The aging population further exacerbates the incidence of AML, as the median age of diagnosis is around 65 years. Consequently, North America is poised to maintain its dominance in the AML market due to these interrelated factors.

Future Market Scenario (2024 - 2031F)

Innovations in measurable residual disease (MRD) diagnosis, which assesses response to treatment and for early detection of imminent relapse, are notable drivers that may translate into futuristic growth of the AML market. A better prognosis and disease diagnosis are key to discovering its prevalence. Thus, AML diagnosis advancements may bring a significant expansion of the market growth rate. The contribution of several market players in the same line is anticipated to drive future market growth. For instance, in June 2024, SOPHiA GENETICS SA, a cloud-native healthcare technology company and a global leader in data-driven medicine, announced its new Residual Acute Myeloid Application. This new offering expands the company's comprehensive oncology portfolio to support MRD capabilities and will be available to customers worldwide. The SOPHiA DDM RAM Solution provides users the confidence that MRD will detect even one cancer cell among 10,000 cells.

Key Players Landscape and Outlook

The AML treatment market is mainly dominated by pharmaceutical and biotechnology giants such as Celgene Corporation, Novartis AG, and Daiichi Sankyo, Inc. Due to the rare disease designation of AML, the market is quite consolidated with a limited number of players. Several startups and small players are working in pre-clinical stages, usually collaborating or getting acquired by larger players. The recent market activities include strategic product launches, regulatory approvals, collaborations for geographic expansion, and acquisition.

In December 2023, VERAXA Biotech AG, a leading company in the development of advanced antibody-based cancer treatments and a portfolio company of Xlife Sciences AG, announced the acquisition of Synimmune GmbH and its innovative Phase I antibody (FLYSYN) for the treatment of Acute Myeloid Leukemia. It represents a significant milestone in the company's history and signifies the expansion of VERAXA's cancer pipeline. The FLYSYN antibody was obtained by VERAXA Biotech AG from Xlife Sciences AG portfolio company Synimmune GmbH through a share deal. The deal involved an initial payment as well as various milestones and is expected to have a total value of approximately USD 35.33 million.

In September 2023, Rigel Pharmaceuticals, Inc. announced that it has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize REZLIDHIA (olutasidenib) in all current and potential indications in Japan, the Republic of Korea and Taiwan. REZLIDHIA is commercially available to patients in the United States for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Acute Myeloid Leukemia Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Disease Subtype
    • 4.2.1.1. Myeloblastic Leukemia
    • 4.2.1.2. Myelomonocytic Leukemia
    • 4.2.1.3. Promyelocytic Leukemia
    • 4.2.1.4. Monocytic Leukemia
    • 4.2.1.5. Others
  • 4.2.2. By Treatment
    • 4.2.2.1. Chemotherapy
      • 4.2.2.1.1. Anti-metabolites
      • 4.2.2.1.2. Alkylating Agents
      • 4.2.2.1.3. Anthracycline Drugs
      • 4.2.2.1.4. Others
    • 4.2.2.2. Targeted Therapy
    • 4.2.2.3. Immunotherapy
    • 4.2.2.4. Hormone Therapy
    • 4.2.2.5. Others
  • 4.2.3. By Route of Administration
    • 4.2.3.1. Parenteral
    • 4.2.3.2. Oral
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Hospitals and Clinics
    • 4.2.4.2. Specialty Centers
    • 4.2.4.3. Ambulatory Surgical Centers
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Disease Subtype
  • 4.3.2. By Treatment
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. North America Acute Myeloid Leukemia Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Disease Subtype
    • 5.2.1.1. Myeloblastic Leukemia
    • 5.2.1.2. Myelomonocytic Leukemia
    • 5.2.1.3. Promyelocytic Leukemia
    • 5.2.1.4. Monocytic Leukemia
    • 5.2.1.5. Others
  • 5.2.2. By Treatment
    • 5.2.2.1. Chemotherapy
      • 5.2.2.1.1. Anti-metabolites
      • 5.2.2.1.2. Alkylating Agents
      • 5.2.2.1.3. Anthracycline Drugs
      • 5.2.2.1.4. Others
    • 5.2.2.2. Targeted Therapy
    • 5.2.2.3. Immunotherapy
    • 5.2.2.4. Hormone Therapy
    • 5.2.2.5. Others
  • 5.2.3. By Route of Administration
    • 5.2.3.1. Parenteral
    • 5.2.3.2. Oral
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospitals and Clinics
    • 5.2.4.2. Specialty Centers
    • 5.2.4.3. Ambulatory Surgical Centers
    • 5.2.4.4. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Acute Myeloid Leukemia Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Disease Subtype
        • 5.3.1.2.1.1. Myeloblastic Leukemia
        • 5.3.1.2.1.2. Myelomonocytic Leukemia
        • 5.3.1.2.1.3. Promyelocytic Leukemia
        • 5.3.1.2.1.4. Monocytic Leukemia
        • 5.3.1.2.1.5. Others
      • 5.3.1.2.2. By Treatment
        • 5.3.1.2.2.1. Chemotherapy
        • 5.3.1.2.2.1.1. Anti-metabolites
        • 5.3.1.2.2.1.2. Alkylating Agents
        • 5.3.1.2.2.1.3. Anthracycline Drugs
        • 5.3.1.2.2.1.4. Others
        • 5.3.1.2.2.2. Targeted Therapy
        • 5.3.1.2.2.3. Immunotherapy
        • 5.3.1.2.2.4. Hormone Therapy
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Route of Administration
        • 5.3.1.2.3.1. Parenteral
        • 5.3.1.2.3.2. Oral
      • 5.3.1.2.4. By Distribution Channel
        • 5.3.1.2.4.1. Hospitals and Clinics
        • 5.3.1.2.4.2. Specialty Centers
        • 5.3.1.2.4.3. Ambulatory Surgical Centers
        • 5.3.1.2.4.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Acute Myeloid Leukemia Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Acute Myeloid Leukemia Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Acute Myeloid Leukemia Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Acute Myeloid Leukemia Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Astellas Pharma Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Bristol Myers Squibb Company
  • 20.3.3. Celgene Corporation
  • 20.3.4. Novartis AG
  • 20.3.5. Daiichi Sankyo, Inc.
  • 20.3.6. Jazz Pharmaceuticals plc
  • 20.3.7. Otsuka Pharmaceutical Co., Ltd.
  • 20.3.8. Partner Therapeutics, Inc.
  • 20.3.9. Pfizer Inc.
  • 20.3.10. Rigel Pharmaceuticals, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer